PSG announces the results of its extensive research on the latest trends in specialty drug benefits.
This exclusive research offers comprehensive insights to assist employers, health plans, labor groups, and other plan sponsors in overseeing specialty drug benefits. This report details a wide range of specialty drug benefit design choices, financial and clinical strategies, goals, challenges, concerns, and needs.
Key Findings
- Specialty Rebates: Receipt of pharmacy rebates remains high, and receipt of medical rebates is rising.
- Biosimilars: Around a third of plans have a Humira biosimilar in a preferred position.
- Cell and Gene Therapies: Most respondents believe affordability of gene therapies will be a moderate or major challenge for their organization in the next 2 to 3 years.
- Top Challenge: Access to reliable data on the total cost of care of medications.
- Top Goals: Manage total cost of care and manage overall specialty trend/specialty drug costs
